Everolimus Plus Exemestane in Advanced Breast Cancer: Safety Results of the BALLET Study on Patients Previously Treated Without and with Chemotherapy in the Metastatic Setting
Daniele Generali(University of Trieste), Gabriella Mariani(Fondazione IRCCS Istituto Nazionale dei Tumori), Donata Sartori(Ospedale di Mirano), Ferdinando Riccardi(Ospedale Antonio Cardarelli), Roberto Bordonaro(Ospedale Garibaldi), Patrizia Vici(Istituti di Ricovero e Cura a Carattere Scientifico), Carlo Barone(Università Cattolica del Sacro Cuore), Giuseppe Portera(Novartis (Italy)), Claudia Bighin(Azienda Ospedaliera S.Maria), Francesco Nuzzo(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Filippo Montemurro(Roche (Switzerland)), Edda Simoncini(International Breast Cancer Study Group), Marina Elena Cazzaniga(Azienda Ospedaliera San Gerardo), F. Goffredo(Novartis (Italy)), Luciano Latini(Ospedale di Macerata), Francesco Cognetti(Apple (Israel)), A. Mafodda(Azienda ospedaliera "Bianchi-Melacrino-Morelli"), Antonio Frassoldati(Italian Oncology Group of Clinical Research), Franco Testore(Ente Ospedaliero Ospedali Galliera), Franco Nolè(European Institute of Oncology), Federico Piacentini(Azienda Unita' Sanitaria Locale Di Modena), Alessandro Marco Minisini, Andrea Michelotti(University of Pisa), Fausto Roila(Roche (Switzerland)), Jennifer Foglietta(Ospedale Santa Maria), S. Romito(Ospedali Riuniti di Foggia), Maria Teresa Ionta(Institute of Genetic and Biomedical Research), Alessio Schirone, Annamaria Molino, Pierluigi Piovano(Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo)
Cited by 11
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
|The Lancet|2007|1.5k
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
|The Lancet Oncology|2015|1.1k